Medicine and Dentistry
Endoscopic Ultrasound
100%
Chronic Pancreatitis
34%
Diagnosis of Chronic Pancreatitis
31%
Elastography
31%
Cystic Pancreatic Lesion
31%
Diagnosis
28%
Intraductal Papillary Mucinous Tumor
28%
Neoplasm
24%
Endoscopic Retrograde Cholangiopancreatography
24%
Autoimmune Pancreatitis
22%
Adverse Event
22%
Pancreas Disease
21%
Retrospective Study
21%
Fine-Needle Aspiration
20%
Adenoma
20%
Adenocarcinoma
20%
Shear Wave Elastography
20%
Biopsy
19%
Pancreas Tumor
19%
Endoscopic Papillotomy
18%
Endoscopic Ultrasound Guided Fine Needle Biopsy
15%
Polyp
15%
Cholangitis
15%
Quantitative Diagnosis
15%
Cholestasis
15%
Liver Surgery
15%
Common Bile Duct
15%
Synapsin II
15%
Bile Duct
15%
Reproducibility
15%
Somatomedin B
15%
Combination Therapy
15%
Bevacizumab
15%
Atezolizumab
15%
Hepatocellular Carcinoma
15%
Sphincter
13%
Bleeding
11%
Papilloma
11%
Liver Transplantation
9%
Hepatectomy
9%
Recurrent Disease
9%
Echography
8%
Bile Duct Cancer
8%
Diagnostic Accuracy
7%
Disease
7%
Diagnostic Imaging
7%
Common Bile Duct Stone
6%
Vascularity
6%
Cholangiography
6%
Extrahepatic Bile Duct
6%
Keyphrases
Atezolizumab Plus Bevacizumab
47%
Endoscopic Ultrasonography
34%
Advanced Hepatocellular Carcinoma
31%
Intraductal Papillary mucinous Neoplasm
28%
Chronic Pancreatitis
25%
Display Method
15%
Medical Ultrasonics
15%
Efficacy Predictor
15%
Transabdominal
15%
Quantitative Diagnosis
15%
Shear Wave Elastography
15%
Hydrogen Concentration
15%
Ultrasonographic Elastography
15%
Breath Hydrogen
15%
Franseen Needle
15%
Ampullary Adenoma
15%
Pancreatic Neoplasms
15%
Shear Wave Velocity Prediction
15%
Elastography
15%
Contrast-enhanced Harmonic Endoscopic Ultrasonography
15%
Pancreatic Cyst
15%
Ultrasonographic Diagnosis
15%
Tumor Assessment
15%
Endoscopic Ultrasound
15%
Complete Response
15%
Clinical Practice
15%
Tremelimumab
15%
Combination Therapy
15%
Elastic Modulus
13%
Normal Pancreas
13%
Atezolizumab
13%
Lenvatinib
12%
Mural Nodule
12%
Bevacizumab
11%
Ultrasound B-mode
10%
Article Use
7%
Bile Duct Tumor
7%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
7%
Autoimmune Pancreatitis
6%
Vascular Function
6%
Affecting Factors
6%
Contrast-enhanced Harmonic EUS
6%
Adverse Events
6%
High Spatial Resolution
5%
Clot
5%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
47%
Atezolizumab
47%
Liver Cell Carcinoma
47%
Adverse Event
18%
Combination Therapy
17%
Pancreas Disease
15%
Tremelimumab
15%
Pancreas Duct Stenosis
15%
Alpha Fetoprotein
15%
Adenoma
15%
Adenocarcinoma
15%
Disease
14%
Lenvatinib
12%
Solid Malignant Neoplasm
12%
Bleeding
11%
Diseases
11%
Recurrent Disease
9%
Remission
9%
Pancreatitis
6%
Retrospective Study
5%
